文献速递血栓与止血MDS 与骨髓增殖性肿瘤

白细胞增多与ET/PV血栓风险的系统综述和荟萃分析

Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.
PubMed 文献 · Blood Adv · 2019-01-01

白细胞增多者血栓相对风险为1.59(95%CI 1.40-1.80),主要来自ET(RR 1.65)和动脉血栓(RR 1.45)亚组,单纯静脉血栓无显著效应。出血(RR 1.87)和死亡(RR 1.89)风险亦被确认。

要点

  • 白细胞增多者血栓风险RR 1.59(95%CI 1.40-1.80),以ET和动脉血栓为主。
  • 单纯静脉血栓亚组白细胞增多效应不显著。
  • 出血RR 1.87、死亡RR 1.89,血液学演变与实体瘤结论不确定。

核心结论

  • 白细胞增多与ET/PV患者血栓风险升高相关(RR 1.59,95%CI 1.40-1.80),主要来自ET和动脉血栓亚组。
  • 时间依赖模型汇总RR提示白细胞在触发血栓机制中可能具因果作用。
  • 白细胞增多对出血(RR 1.87)和死亡(RR 1.89)的效应被确认。

研究设计与样本

  • 系统综述与荟萃分析,按预设方案检索近12年发表的文献。
  • 除血栓外,还收集出血、血液学演变、第二肿瘤和死亡数据。

主要发现

  • 白细胞增多者血栓RR 1.59(95%CI 1.40-1.80),ET亚组RR 1.65(95%CI 1.43-1.91),动脉血栓亚组RR 1.45(95%CI 1.13-1.86)。
  • 单纯静脉血栓亚组白细胞增多效应不显著。
  • 出血RR 1.87(95%CI 1.26-2.77),死亡RR 1.89(95%CI 1.59-2.23)。
  • 血液学演变和实体瘤的结论不确定。
  • 以复发事件为结局及调整或未调整混杂因素的白细胞估计敏感性分析均证实主要结果。

关键数值与推荐

  • 白细胞增多时血栓相对风险RR 1.59(95%CI 1.40-1.80)。
  • ET亚组血栓RR 1.65(95%CI 1.43-1.91)。
  • 动脉血栓亚组RR 1.45(95%CI 1.13-1.86)。
  • 出血RR 1.87(95%CI 1.26-2.77)。
  • 死亡RR 1.89(95%CI 1.59-2.23)。

临床怎么用

  • 原文未述及具体临床实践建议。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the last years, a growing amount of evidence has been produced regarding the role of leukocytosis as a risk factor for thrombosis in patients with myeloproliferative neoplasms, predominantly in polycythemia vera (PV) and essential thrombocythemia (ET). Results from epidemiologic studies on this issue, however, are inconclusive. We conducted a systematic review and meta-analysis of articles published in the last 12 years addressing the issue, according to a predefined protocol. Forty-one articles analyzing >30 000 patients met our inclusion criteria and were deemed of acceptable methodologic quality. In addition to data on thrombosis, data were collected on bleeding, hematologic evolution, secondary cancer, and death. The relative risk (RR) of thrombosis in the presence of leukocytosis was 1.59 (95% CI, 1.40-1.80), mainly accounted for by ET (RR, 1.65; 95% CI, 1.43-1.91) and arterial thrombosis (RR, 1.45; 95% CI, 1.13-1.86) subgroups; the effect was not significant in venous thrombosis alone. Sensitivity analyses considering recurrent events as well as white blood cell estimates adjusted or unadjusted for confounding factors confirmed the primary results. In addition, the pooled RR of studies that tested white blood cell counts in time-dependent models suggested a causative effect of leukocytes in the mechanism that triggers thrombosis. The effect of leukocytosis on bleeding (RR, 1.87; 95% CI, 1.26-2.77) and death (RR, 1.89; 95% CI, 1.59-2.23) was confirmed, whereas conclusions on hematologic evolutions and solid tumors were uncertain. To confirm the accuracy of these results, an investigation on individual patient data in a large collective archive of homogeneous patients is warranted.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Carobbio A, Ferrari A, Masciulli A, et al. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019. PMID: 31175128. doi:10.1182/bloodadvances.2019000211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。